Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs New York Times Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while New York Times Co trades at $75 (market cap $12.13B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.3× New York Times Co's market cap, and New York Times Co pays a 1.23% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NYT | |
|---|---|---|
Market Cap | $39.89B | $12.13B |
Sector | Health | Media |
52-Week High | $491.22 | $85.86 |
52-Week Low | $278.09 | $51.43 |
Enterprise Value | $38.15B | $11.53B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
The New York Times (NYT) stock trades at $74.96, up 0.89% on the day, reflecting steady growth. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $0.61 surpassing the $0.47 expectation. Revenue reached $2.82B in 2025, with net income margin improving to 12.17%. Technical indicators show a bullish trend, while analyst consensus is a $78 price target. Recent news highlights legal actions involving OpenAI and government subpoenas, adding to operational scrutiny.
Outlook remains positive due to strong earnings performance and revenue growth, but risks include legal battles and regulatory pressures. The stock offers potential upside to the consensus target, supported by solid cash flow and profitability metrics. Investors should weigh these factors against ongoing litigation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
